Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595073 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
A Phase 3 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT02595073 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 124 participants.
The verdict
NCT02595073, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
Interventions
- DRUG Placebo
- DRUG DSXS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2015-09-04 |
| Est. Completion | 2017-08-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595073
The ClinicalTrials.gov registry entry for NCT02595073 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02595073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595073 about?
NCT02595073 is a clinical study titled "Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis". Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
What is the current status of trial NCT02595073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2015-09-04. Estimated completion is 2017-08-29.
What interventions are being tested in trial NCT02595073?
The interventions under investigation include: Placebo (DRUG), DSXS (DRUG).
Who is sponsoring clinical trial NCT02595073?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.